As at 31 March 2012, the company had $257m in debt. DLX has stated that the cash offer for ALS will be fully debt funded. At $2.00 per share, which has now been rejected, the offer is $188m. If DLX pursue the acquisition they are likely to pay upwards of $200m, taking debt to $450-$500m.
While a quality business with a great brand, I think the fully debt funded acquisition will significantly increase the risk of DLX both operating risk through the integration of the businesses and financial risk as a result of the increased leverage.
I am perhaps, overly conservative when it comes to debt, but I like to protect my hard earned $$$.
- Forums
- ASX - By Stock
- DLX
- buy?
buy?, page-5
Featured News
Add DLX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online